Introduction
Malignant tumors are the second leading cause of death in industrial countries. Many malignant tumors show either initial or acquired resistance to chemotherapy, which makes them very difficult to cure when detected in advanced stages and in the case of relapse. Acute lymphoblastic leukemia (ALL), the most common pediatric cancer, accounts for 75% of all cases of childhood leukemia. With wider use of intensive chemotherapy, the prognosis for childhood ALL has improved remarkably 1 but the outcomes for patients with relapsed ALL remain poor. 2 This highlights the need for the development of novel tools for the investigation of mechanisms underlying ALL progression and for screening of potential therapeutics. Among currently available models of malignant tumors, transplantable mammalian tumor lines induced and maintained in inbred animals are a gold standard for carrying out such screenings. However, the cost, ethical constraints and limited availability of these models for high throughput (HTP) assays urge the development of alternative screening systems in oncology.
The zebrafish, a very promising and rapidly developing model in cancer research, 3 is a feasible alternative to tumor models in rodents. The very similar to those in mammals. Indeed, most of the tumors induced in zebrafish by either carcinogens or oncogenic transgenes demonstrate ability to invasive growth and metastasis; they can also be successfully transplanted into either syngeneic or immunosuppressed recipients. [4] [5] [6] These features are also characteristic for zebrafish models of leukemia caused by transgenic oncogenes specifically expressed in lymphocyte progenitor cells. 7 However, direct evidence that malignant tumors including leukemia induced in zebrafish are sensitive to standard chemotherapeutic drugs broadly used for cancer treatment in human and in rodents has not yet been demonstrated. This kind of study is an indispensable step towards validation of utilization of zebrafish for screening of not only individual compounds with antitumor activity but even chemical libraries. However, the lack of transplantable leukemia lines which would facilitate production of hundreds of zebrafish bearing synchronously growing tumors has constrained such a study. To overcome this problem we generated a new transplantable fluorescence-tagged T-ALL line induced by injection of zRag2-EGFP-mMyc fusion gene construct into 1-cell stage embryos essentially as described before. 8 We used a novel clonal homozygous zebrafish line CG2 obtained by a double heat-shock gynogenesis 9 as a background for leukemia induction and were able to carry out transplantation of tumor cells from one fish to another without rejection of the transplant.
10,11
The efficacy of cyclophosphamide (CY), vincristine (VCR) and prednisolone (pRe) were studied in leukemia-bearing zebrafish larvae. a transplantable T cell acute lymphoblastic leukemia (T-aLL) line ZL1 was induced by mosaic expression of zRag2-eGFp-mMyc transgene and underwent more than 20 consecutive transplantations in adult syngeneic fish prior to the experiments. Drug efficiency was assessed by an increase of lifespan (ILs) of treated leukemia-bearing animals as compared with untreated leukemia-bearing animals. Different doses of the drugs and length of the treatment were tested. CY and VCR demonstrated therapeutic effect which was dose-and time course-dependent. The maximal increase of ILs reached 61.1% after CY (400 mg/L, 72 hours) treatment and 44.4%-in VCR (4 mg/L, 72 hours) treated animals. None of the tumor-bearing larvae showed complete recovery from leukemia as a result of any VCR and CY monotherapy schedule. pRe was inefficient for treatment of leukemia in zebrafish in a dose range between 1 and 50 mg/L and a treatment length between 24 and 72 hours due to it toxicity exclusively towards leukemia-bearing larvae. These data demonstrate that, in addition to morphological and genetic similarities with mammalian leukemia, zebrafish T-aLL is also sensitive to the same chemotherapeutic drugs in vivo as mammals. Therefore, this model can be utilized as a cost effective system for experimental tumor therapy and large-scale screening of anticancer compounds.
and showed minimal contamination with GFP negative cells, mostly erythrocytes.
Injection of 4.6 nl leukemic cell suspension (1.0 or 2.5 x 10 7 cells/ml) into the peritoneal cavity of 5-day old larvae led to emerging signs of leukemia such as intensive GFP fluorescence around thymus areas and peritoneum followed by enlargement of the abdominal area as soon as 4-5 days after the engraftment ( Fig. 2D-F) . The growth rate of transplanted leukemia directly correlated with the quantity of engrafted cells. Beginning Day 7, the leukemia-bearing larvae were gradually becoming less mobile, were settling at the bottom of the well and stopped eating. By that time, the majority of larvae developed ascites and demonstrated an apparent decrease in the heart rate. These signs together with lack of larva movement in response to a touch with a needle tip indicated that their death was imminent within 24 hours. Leukemia treatment. Treatment of leukemia-bearing larvae with antitumor drugs typically began on Day 5 after the leukemia engraftment. By this time, the tumor mass reached significant size leading minimum to 2-fold increase of body width in leukemia-bearing larvae as compared to leukemia free larvae ( Fig. 2B and C) .
The main results of the study are presented in Table 1 . We found that VCR and CY had a substantial therapeutic effect assessed by increase of lifespan (ILS) of leukemia-bearing larvae compared to control (untreated) leukemia-bearing larvae. ILS as a result of the chemotherapy was clearly dose-and time coursedependent. In the first experiment, the most efficient dose of VCR appeared to be 5 mg/L with a substantial antitumor effect (ILS > 25%) in all treatment schedules. In particular, this dose of In this study, for the first time, we present data evaluating efficacy of chemotherapeutic drugs such as vincristine (VCR), cyclophosphamide (CY) and prednisolone (PRE), widely used for treatment of hematologic malignancies in human, 12 in a leukemia model in zebrafish.
Results
Leukemia line generation and transplantation. Transplantable leukemia line ZL1 was induced by injection of zRag2-EGFPmMyc fusion gene construct into CG2 clonal zebrafish embryos at 1-cell stage essentially as described by Langenau et al. 8 The tumor growth was first detected in a 3-week old fish as a typical green fluorescence around the thymus area. In experiments on tumor chemotherapy, we used ZL1 leukemia that had already undergone more than 20 consecutive engraftments in syngeneic animals. During this period leukemia did not reveal substantial changes in cell morphology, biological behavior and the levels of GFP expression.
Progressive tumor growth in adult animals occurred mostly in the peritoneal cavity ultimately leading to almost synchronous host lethality within 9-12 days after an intraperitoneal (i.p.) engraftment of the leukemia cells. Grossly, the tumor emerged as a moderate enlargement of abdominal area which reaches its maximum 2-3 days prior fish death (Fig. 1A-C) . At necropsy, the tumor appeared as a white jelly mass filling the entire peritoneal cavity of the fish (Fig. 1D) . This mass demonstrated homogenous GFP fluorescence under a fluorescent stereomicroscope (Fig. 1E) . The leukemia cells could be easily dissociated by gentle pipetting the tumor in phosphate buffered saline (PBS) The treatment with therapeutic doses of either VCR or CY caused a sharp reduction of abdominal volume in leukemiabearing larvae and normalization of their swimming behavior. A maximal therapeutic effect of VCR and CY occurred on 2 nd -3 rd days after termination of treatment followed by a gradual recurrence of the leukemia growth. We did not see a single case of a complete recovery from leukemia in larvae treated with any antitumor drug used in this study. PRE within dose range 10-50 mg/L caused moderate toxic effect decreasing MST in leukemia-bearing larvae. Interestingly, the toxicity did not significantly depend upon doses of the PRE and treatment length.
In the second experiment, we modified doses of the drugs, increased the concentration of engrafted leukemia cells up to 2.5 x 10 7 cells/ml (∼100 cells/animal) and used 72-hour treatment protocol only. The results of this experiment appeared to be similar to the first one (Fig. 3) . In particular, VCR and CY demonstrated similar dose-dependent activity in regards of ILS in leukemia-bearing larvae ( Table 1) . The log-rank test for multiple groups which evaluated dose-effect of the treatment indicated significant positive trends in the efficacy of treatment for both VCR (p = 0.002) and CY (p = 0.0007). The ILS of larvae in groups treated with either 4 mg/L VCR or 400 mg/L CY was more prominent-44.4% (p < 0.001) and 61.1% (p = 0.00002), respectively. The maximal lifespan of leukemia-bearing larvae that underwent treatment with either 4 mg/L VCR or 400 mg/L CY reached 21 and 22 days, respectively. VCR caused 26.3% (p = 0.059), 42.1% (p = 0.006) and 31.6% (p = 0.02) ILS in the leukemia-bearing larvae in 24-, 48-and 72-hour treatment protocols, respectively. A lower dose of VCR, 2.5 mg/L did increase survival time of the leukemia-bearing larvae to 5.3% (p = 0.52), 31.6% (p = 0.17) and 26.3% (p = 0.09) after 24-, 48-and 72-hour treatment, respectively, although these increases were not statistically significant. The maximal dose of VCR used in our experiments, 10 mg/L, increased survival of the leukemia-bearing larvae up to 31.6% after 24-hour treatment only. However, this effect of VCR was also not statistically significant (p = 0.14).
The maximal dose of CY (300 mg/L) caused 10.5% (p = 0.76), 15.8% (p = 0.84) and 31.6% (p = 0.19) ILS in leukemiabearing larvae after 24-, 48-and 72-hour treatment, respectively. This effect of CY was also not statistically significant. By contrast, log-rank test of the survivor function across multiple groups of leukemia-bearing larvae treated with 300 mg/L CY for either 24, 48 or 72 hours did reveal significant effect of treatment (p = 0.04).
Lower doses of CY (100 mg/L and 200 mg/L) either did not affect ILS in leukemia-bearing larvae after 24 hours treatment at all or slightly increased animal median survival time (MST) in 48-and 72-hour treatment regimens (5.3-15.8%, p > 0.05). Nevertheless, log-rank test for multiple groups which evaluated dose-effect of the treatment indicated significant positive trends for 48-(p = 0.002) and 72-hours (p = 0.0008) in CY treatment efficacy. Leukemia growth in larvae. a 6-well plate with inserted 100 µm Nylon Cell strainer was able to house 10 larvae/well for up to 20 days (a). Dorsal view of 15 dpf control (B) and leukemia-bearing larvae (C) 10 days after leukemia cell engraftment. Typical enlargement of the larval body as a result of leukemia growth. Lateral view of 15 dpf larvae with massive infiltration of abdominal area spreading towards the thymus area 10 days after leukemia engraftment. Development of ascites (arrow) in peritoneal cavity of leukemia engrafted larvae is a typical symptom of terminal stage of leukemia progression; asterisk indicates a site of leukemia cell injection, bright field (D); wide field fluorescent microscopy (e) and digitally merged bright field and fluorescent images (F), leukemia cell homing to thymus area (arrow).
of MST decrease in leukemia-bearing larvae (down to 7.5 and 8 days, respectively) after 72-hour treatment. This suggests that the toxicity of PRE on leukemia-bearing larvae is exclusively due to a treatment length with PRE rather than due to a drug dose.
Surprisingly, lower doses of PRE used in the second experiment (1, 2.5 and 5 mg/L) still resulted in a decreased MST of leukemiabearing larvae. Moreover, maximal (50 mg/L) and minimal (1 mg/L) doses of PRE used in this study resulted in close levels 
Discussion
Two cytostatic drugs, VCR and CY (broadly used in therapy of ALL in humans), demonstrated antitumor activity (ILS > 25%) in leukemia-bearing larvae. As expected, this effect correlated with the dose of the drugs and time course of the treatment. This observation is in a good agreement with data showing high sensitivity of T-ALL induced in zebrafish to γ-irradiation. Germ line transgenic zebrafish constitutively overexpressing mMyc and readily developing T-ALL show dramatic regress of the tumor following γ-irradiation, while both overexpression of transgenic bcl-2 and p53 deficiency in T-ALL suppress apoptosis caused by γ-irradiation.
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By contrast, PRE in a wide dose range was ineffective in this model of T-ALL while 10 and 50 mg/L PRE caused partial or complete ablation of normal Rag2-positive cells in thymus in leukemia-free larvae after 72-hour treatment. This observation is in a good agreement with data demonstrating that another glucocorticoid, dexamethsone (DEX) causes profound immunosupression in juvenile fish at 10 mg/L 14 and induces apoptosis of T lymphocytes in 5-day embryos in a dose range between The survival of transgenic rag2:GFP larvae in control and PRE (1 and 10 mg/L for 72 hours) treated groups was 100% after 3 days of observation. A higher dose of PRE (50 mg/L) led to survival of only 3 out 5 larvae. The levels of GFP expression in thymus in larvae treated with minimal dose of PRE (1 mg/L, Fig. 4B ) was the same as in the control group (Fig. 4A) . Treatment with 10 mg/L PRE caused more than 50% ablation of T-lymphocytes in thymus assessed by the levels of GFP fluorescence (Fig. 4C) . Treatment of larvae with 50 mg/L PRE resulted in complete ablation of T-lymphocytes in thymus in surviving larvae and sharp retardation of the animal development as compared with larvae treated with lower doses of PRE (Fig. 4D) .
Leukemia-free PBS-injected larvae treated with 400 mg/L CY, 5 mg/L VCR or 1 mg/L PRE for 72 hours demonstrated 100% survival during 3-week period of observation. These doses of the drugs did not affect the growth rate of the larvae indicating low toxicity of CY and VCR in leukemia-free larvae. By contrast, increased doses of PRE such as 10 mg/L and 50 mg/L did cause 30% and 20% larvae lethality, respectively, within 10 days after beginning of the treatment. of antitumor therapy efficiency in an animal model requires a synchronous leukemia growth which provides an opportunity for a highly accurate evaluation of a drug effect. In our model, full fetched T-ALL developed in larvae by Day 5 after tumor cell engraftment. By this time, leukemia emerged in a generalized form and could rapidly be assessed visually under a fluorescent stereomicroscope. Larvae with leukemia growth rate which deviated significantly from the majority of leukemia-bearing larvae in the group (usually 1-5%) can be selected out at this stage.
A comparison of biological behavior of ZL1 zebrafish leukemia line with a popular murine lymphoblastic leukemia model, namely p388, demonstrated a striking similarity between these two models. [20] [21] [22] [23] [24] In particular, the typical feature of both ZL1 and P388 leukemic lines is fast and synchronous death of the inoculated animals with median survival 9-13 days, quick dissemination of tumor growth and development of ascites in the terminal stage of leukemia. Moreover, the effective therapeutic doses of CY in the murine model are 100-400 mg/kg vs. 200-400 mg/L in fish and for VCR-0.1-2.5 mg/kg in mice vs. 2.5-4 mg/L in fish. It is also noteworthy that toxic doses of different drugs in rodents and fish expressed in mg/kg and mg/L, respectively, are practically identical. 25 These observations make it easier to extrapolate studies carried out in rodents to a fish model and vice versa, with the perspective of substituting certain rodent models with similar antitumor therapy models in fish.
25-250 mg/L. 15 In our experiments, doses of PRE which caused 100% ablation of Rag2-positive cells after a 72-hour treatment were toxic for both intact and leukemia-bearing larvae. This suggests that T-ALL in zebrafish, unlike normal lymphocytes, have increased resistance to apoptosis induced by glucocorticoids. In case of ZL1 T-ALL line, resistance to PRE-induced apoptosis may be linked to constitutive expression of MYC oncogene in leukemic cells, a conclusion supported by data on increased resistance towards DEX-induced cytolysis in vitro in c-myc transfected leukemic cells. 16 The maximal lifespan extension in leukemia-bearing larvae treated with 400 mg/L CY for 72 hours reached 61.1%. Nevertheless, none of the tumor-bearing larvae underwent sustainable remission as a result of any VCR and CY monotherapy schedule. Recurrence of leukemia growth usually occurred 3-5 days after termination of the treatment. A relatively modest effect of chemotherapy on T-ALL in zebrafish larvae as compared to standard mouse leukemia models such as p388 and L1210 was likely a result of the advanced stage of leukemia by Day 5 after ZL1 cell transplantation. By contrast, in the majority of murine models, superior results in the experimental therapy of leukemia were obtained if the treatment began on Day 1 after transplantation of leukemic cells. 17, 18 In experiments where the treatment began several days after a leukemia transplantation, efficiency of therapy significantly decreased. 19 However, a quantitative assessment on ice. The cells were engrafted to 5 dpf syngeneic larvae using microinjector Nanoliter 2000 (WPI, Sarasota, FL). In a typical experiment, 25-50 larvae immobilized in 0.0015% tricaine (Sigma-Aldrich, St. Louis, MI) were placed on a wet filter paper in a ∅100 mm plastic Petri dish by a Pasteur pipette so that the larvae were barely covered by water but remained well moisturized. Using a preparative needle the larvae were oriented so that they were aligned in one line. Total 5-10 µl of the leukemia cell suspension was placed into the injection tip of a glass micropipettes (inner ∅25 µm). Each larva was injected i.p. into a site just posterior from the swim bladder (Fig. 2D ) in 4.6 nl of cell suspension (∼50 or 100 cells per animal). Immediately after the injections the larvae were transferred to system water for recovery. This procedure was repeated several times to produce up to 500 leukemia engrafted larvae within less than 2 hours. Control larvae were injected with the same volume of 0.9X PBS as leukemia engrafted animals. Between the tumor engraftment and beginning of treatment with a drug, the larvae were maintained in 2.6 L plastic tanks (Aquaneering, San Diego, CA) at 28.5°C. Approximately 70% of water in the tank was daily replaced with fresh system water. The larvae were fed with Paramecia two times per day. The survival of larvae by Day 5 after leukemia engraftment exceeded 90%. All survived larvae showed signs of leukemia growth. Experimental therapy of T-ALL. Vincristine sulfate (SigmaAldrich, St. Louis, MI) and cyclophosphamide monohydrate (Sigma-Aldrich, St. Louis, MI) were dissolved in distilled water at concentration 1 and 15 mg/ml, respectively. Fresh solutions were aliquoted and kept at -20°C until the experiment. Prednisolone (Sigma-Aldrich, St. Louis, MI) was dissolved in egg water 33 at concentration 50 mg per 1 L and was kept up to 1 month at 4°C in dark. After 5 days of housing in 2.6 L tank, 10 dpf leukemia-bearing larvae were immobilized in 0.0015% tricaine solution and analyzed under fluorescent stereomicroscope Discovery V8 (Zeiss, Germany) with GFP filter. About 5% larvae with either weak or extremely high level of fluorescence were discarded on this stage. The remaining larvae were placed in 6-well plates with 100 µm Nylon Cell Strainer (BD Falcon, San Jose, CA) inserts, 10 larvae per well (Fig. 2A) . The wells were filled with 10 ml of either a drug dissolved in system water or system water alone. After 24-to 72-hour treatment the larvae were 'washed out' of the residual drug by several consecutive exchanges of fresh system water. The transfer of the larvae into fresh water in a new 6-well plate was carried out together with a cell strainer which made this procedure fast and harmless for the larvae. On this step of the experiment, water in the 6-well plate was completely exchanged every other day. The fish were fed with live Paramecia which was washed and concentrated up to about 1,000 cell/ml using paper filter. Daily, 25-50 µl suspension of the Paramecia was added to each well. In these conditions, the larvae could be maintained in a 6 well plate for up to 3 weeks. Inspection of the larvae under a stereomicroscope was carried out twice per day.
As per IACUC regulations we avoided using animal death as an end-point in this study. As an alternative, we used a panel of visual signs indication that the death is imminent within 24
Unlike screening of antitumor drugs in vitro in cell culture, the proposed whole animal model allows assessment of antitumor activity, and general and organ specific (side effects) toxicity in one assay. Moreover, this model is suitable for studying compounds which require metabolic activation without using either host-or in vitro S9 microsomal fraction-mediated activation of a drug. 26 In particular, the effectiveness of CY, which is converted into an active metabolite by enzymatic systems in liver, 27 against ZL1 leukemia in vivo demonstrates the maturity of these systems in 10-13 day old larvae. In addition, the transplantable tumor model in syngeneic (i.e., non-immunosuppressed) animals enables accurate assessment of broad host organism responses to a tumor such as an immune response 28 and angiogenesis. 29 The small size of zebrafish, and the possibility of using transparent larvae and embryos for tumor transplantation open additional opportunities for carrying out large scale experiments using a multi-well plate technology 30, 31 and for in vivo imaging. 32 These data demonstrate for the first time that zebrafish T-ALL has not only close morphological and genetic similarities with mammalian leukemia but is also sensitive to the same antitumor chemotherapy in vivo. Therefore, this model can be utilized as a cost effective system for experimental tumor therapy and largescale screening of anticancer drugs, especially those targeting specific Myc-depending oncogenic pathways.
Materials and Methods
Animals. Transgenic zebrafish line Tg(rag2:GFP) was obtained from Zebrafish International Resurce Centre (ZIRC, Oregone). Clonal line CG2 derived from golden zebrafish strain (obtained from Dr. H.G. Frohnhoefer, MPI for Developmental Biology, Germany) have been generated by two consecutive rounds of heat shock procedure as described earlier. 9, 10 This line has been maintained in the lab for 10 generations. Fish were housed at 28°C with 14:10 day/night circle as recommended. 33 All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committees (IACUC).
Leukemia cell line. T cell acute lymphoblastic leukemia line ZL1 was induced by microinjection of zRag2-EGFP-mMyc construct (obtained from A.T. Look, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA) in 1-cell CG2 embryos essentially as described by Langenau et al. 8 and was maintained in vivo by serial transplantations to syngeneic fish. The experiments have been carried out on ZL1 line which had undergone >20 consecutive i.p. transplantations to CG2 fish. Typical transplantation was carried out using 25 µl of leukemic cell suspension (∼0.5 x 10 6 cells/ml) in 0.9X phosphate buffered saline (PBS) injected into 4-6 months old male fish.
Transplantation of leukemic cells to syngeneic larvae. Leukemia cells were collected from a single tumor-bearing fish 10 days after a leukemia engraftment by abdominal lavage, and were mechanically dispersed in 500 µl of 0.9X PBS and washed in PBS at least 3 times. The homogeneity of GFP-expressing cells has been inspected under fluorescent microscope. Prior to the microinjection into larvae the cells were resuspended in 30-50 µl 0.9X PBS at concentration 1-or 2.5 x 10 7 cells/ml and were kept stereomicroscope Discovery V8 at 10 to 30x magnification and AxioVision 4.6 software (Zeiss, Germany). ImageJ software (NIH Image) was used to measure the larva body width. The fluorescent and bright field images were merged using Photoshop CS4 software (Adobe Systems). Assessment of antitumor activity and statistical analysis. The assessment of antitumor activity of the tested drugs was mostly based on the increase of lifespan of larvae in treated groups vs. a control (untreated) group. 34 The ILS was calculated as following: ILS(%) = [(MSTt/MSTc) x 100] -100 where MSTt-the median survival time of the treated group, and MSTc-the median survival time of the control group. It was assumed that ILS of the treated group compared with the control group by 25% indicated anti-leukemia activity of the drug. Statistical analysis of the study was performed using BioStat software (version 2009, AnalystSoft). We used Kaplan-Meier method for calculating and analysis of survival curves. The efficacy of treatment as a function of length of treatment and dose of a drug was calculated using a long-rank test for trend. Differences were considered significant at p ≤ 0.05.
hours, such as lack of food consumption by the larvae, their settling at the bottom of a well, lack of movement in response to a touch with a needle tip, development of ascites and sharp decline in the heart rate. Larvae that entered the moribund state were removed from the well and euthanized in tricaine solution. The survival time was calculated as a period of time between tumor implantation and euthanasia plus 1 day.
Control groups, each consisting of 10 larvae, were injected with 4.6 nL 0.9X PBS, were treated for 72 hours with maximal tolerabledoses of either CY or VCR determined in preliminary toxicological tests. The larvae in control, leukemia free groups, were monitored for up to 25 days which corresponded to the maximal survival time of leukemia-bearing larvae.
Prednisolone treatment of rag2:GFP transgenic fish. Fiveday old larvae were treated with either 1, 10 or 50 mg/L PRE for 72 hours. The control larvae were housed in the same conditions without PRE. Each group consisted of 5 larvae. Immediately after termination of the treatment the larvae were examined under a fluorescent stereomicroscope to assess the levels of Rag2-positive cells estimated by GFP fluorescence in thymus.
Image acquisition and measurements. In order to capture the images, larvae were immobilized in 0.0015% tricaine and placed in a ∅60 mm Petri dish with 2-3 mm 1% agarose layer covered with tricaine solution. The larvae were oriented in a desirable position in v-shape grooves made manually with a scalpel blade in the agarose to fit the larva body. The images were captured by a digital camera AxioCam MRc (Zeiss, Germany) using fluorescent
